Dose-Ranging Study of BAY 59-7939 on the Prevention of VTE in Patients Undergoing Elective Total Hip Replacement

Venous Thromboembolism Clinical Trial

— ODIXa-HIP2  

Official title:

Controlled, Double-Blind, Randomised, Dose-Ranging Study on the Prevention of VTE in Patients Undergoing Elective Total Hip Replacement- ODIXa-HIP2 Study BAY 59-7939

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00398905
• Other study ID #: 10944
• Status: Completed
• Phase: Phase 2
• First received: November 7, 2006
• Last updated: May 7, 2009
• Start date: January 2004
• Est. completion date: September 2004

Study information

• Verified date: May 2009
• Source: Bayer
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

Patients undergoing surgery, especially hip and knee surgery, are at high risk for VTE. The administration of drugs for thromboprophylaxis, such as heparins, significantly lowers that risk, but heparins have to be applied by injections below the skin. The purpose of this study was to compare the safety and efficacy of BAY 59-7939 with the safety and efficacy of the licensed drug enoxaparin and to find the optimal dose of BAY 59-7939 for the anticipated phase III trials. Enoxaparin, a so-called low molecular weight heparin, is approved and widely used in the area of thromboprophylaxis and was given once daily subcutaneously. In this study 5 different doses of the investigational drug BAY 59-7939 were tested in comparison to Enoxaparin. The following doses of BAY 59-7939 were tested: 2.5 mg twice daily (5 mg total daily dose); 5 mg twice daily (10 mg total daily dose), 10 mg twice daily (20 mg total daily dose), 20 mg twice daily (40 mg total daily dose) and 30 mg twice daily ( 60 mg total daily dose). This study ran for approximately 7 months in a number of countries. In total, 726 patients were enrolled in this study.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 726
• Est. completion date: September 2004
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Male patients aged 18 years or above and postmenopausal female patients

• Patients scheduled for elective primary total hip replacement (cemented or non-cemented prosthesis

• Patients written informed consent for participation after receiving detailed written and oral previous information to any study specific procedures

Exclusion Criteria:

• Any VTE prior to randomization

• Myocardial infarction (MI) or TIA or ischaemic stroke within the last 6 months prior to randomisation

• History of heparin-induced thrombocytopenia, allergy to heparins

• Intracerebral or intraocular bleeding within the last 6 months prior to randomisation

• History of gastrointestinal disease with gastrointestinal bleeding within the last 6 months prior to the study

• History or presence of gastrointestinal disease which could result in an impaired absorption of the study drug (e.g. severe active inflammatory bowel disease, short gut syndrome)

• Amputation of one leg

• Heart insufficiency NYHA III-IV

• Congenital or acquired haemorrhagic diathesis (PT INR/aPTT not within normal limits) including patients with acquired or congenital thrombopathy

• Thrombocytopenia (platelets < 100.000/µl)

• Macroscopic haematuria.

• Allergy to contrast media.

• Severe hypertension (SBP > 200mmHg, DBP > 100 mmHg)

• Impaired liver function (transaminases > 2 x ULN)

• Impaired renal function (serum creatinine > 1.5 x ULN or creatinine clearance < 30 ml/min)

• Active malignant disease

• Presence of active peptic ulcer or gastrointestinal disease with increased risk of gastrointestinal bleeding

• Body weight < 45 kg

• Drug- or alcohol abuse

• Patients who cannot stop therapy ( in the opinion of the investigator/ physician) with anticoagulants (e.g. phenprocoumon, warfarin-sodium, heparins and factor Xa inhibitors other than study medication) and fibrinolytic therapy should be excluded from the study

• Therapy with acetylic salicylic acid or other thrombocyte aggregation inhibitors (e.g. clopidogrel, dipyridamole and ticlopidine) should be stopped one week before enrolment. Patients not able to stop ASA therapy will be excluded

• All other drugs influencing coagulation, (exception: NSAIDs with half life < 17 hrs will be allowed)

• Systemic and topical treatment with azole compounds (e.g. ketoconazole, fluconazole, itraconazole) and other strong CYP3A4 inhibitors e.g. HIV-protease inhibitors. Azole compounds and other strong CYP3A4 inhibitors

• Therapy with another investigational product within 30 days prior start of study

• Planned intermittent pneumatic compression during active treatment period

• Planned epidural anaesthesia with indwelling epidural catheter (spinal or epidural anaesthesia without indwelling catheter are allowed)

• Concomitant participation in another trial or study

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention

Related Conditions & MeSH terms

• Thromboembolism
• Venous Thromboembolism

Intervention

Drug:
• Rivaroxaban (Xarelto, BAY59-7939)
2,5 mg twice daily (5 mg total daily dose)
• Rivaroxaban (Xarelto, BAY59-7939)
5 mg twice daily (10 mg total daily dose)
• Rivaroxaban (Xarelto, BAY59-7939)
10 mg twice daily (20 mg total daily dose)
• Rivaroxaban (Xarelto, BAY59-7939)
20 mg twice daily (40 mg total daily dose)
• Rivaroxaban (Xarelto, BAY59-7939)
30 mg twice daily (60 mg total daily dose)
• Enoxaparin
40 mg once daily (40 mg total daily dose)

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Bayer

Countries where clinical trial is conducted

Austria,  Belgium,  Denmark,  France,  Germany,  Israel,  Italy,  Netherlands,  Norway,  Poland,  Spain,  Sweden,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Composite Endpoint: Any Deep Vein Thrombosis (DVT) (proximal and/or distal) and Non fatal Pulmonary Embolism (PE) and Death from all causes		5-9 days after surgery
Secondary	Incidence of DVTs (total, proximal, distal)		5-9 days after surgery
Secondary	Incidence of symptomatic Venous Thrombo Embolisms (VTEs)		5-9 days after surgery
Secondary	Incidence of symptomatic VTEs (total, PE, DVT) within 30 days after stop of treatment with the study drug		40 days
Secondary	Healthcare Resource Utilisation Questionnaire		9 days and 40 days after surgery

External Links

•   Click here and search for drug information provided by the FDA
•   Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product